A detailed history of Cubist Systematic Strategies, LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 358,071 shares of SNDX stock, worth $4.91 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
358,071
Holding current value
$4.91 Million
% of portfolio
0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$12.52 - $21.81 $4.48 Million - $7.81 Million
358,071 New
358,071 $4.73 Million
Q3 2023

Nov 14, 2023

BUY
$14.52 - $21.77 $2.79 Million - $4.18 Million
192,094 New
192,094 $2.79 Million
Q1 2023

May 15, 2023

BUY
$20.66 - $28.98 $163,627 - $229,521
7,920 New
7,920 $167,000
Q2 2022

Aug 15, 2022

SELL
$13.64 - $19.48 $788,446 - $1.13 Million
-57,804 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$14.84 - $22.15 $299,857 - $447,562
20,206 Added 53.74%
57,804 $1.01 Million
Q4 2021

Feb 14, 2022

BUY
$15.23 - $22.47 $322,952 - $476,476
21,205 Added 129.35%
37,598 $823,000
Q3 2021

Nov 15, 2021

SELL
$13.87 - $19.8 $66,201 - $94,505
-4,773 Reduced 22.55%
16,393 $313,000
Q2 2021

Aug 16, 2021

BUY
$13.42 - $25.18 $59,249 - $111,169
4,415 Added 26.36%
21,166 $363,000
Q1 2021

May 17, 2021

SELL
$19.28 - $24.59 $341,178 - $435,144
-17,696 Reduced 51.37%
16,751 $375,000
Q4 2020

Feb 16, 2021

BUY
$15.1 - $26.44 $403,879 - $707,190
26,747 Added 347.36%
34,447 $766,000
Q3 2020

Nov 16, 2020

SELL
$13.39 - $17.48 $103,919 - $135,662
-7,761 Reduced 50.2%
7,700 $114,000
Q2 2020

Aug 14, 2020

BUY
$8.94 - $20.98 $138,221 - $324,371
15,461 New
15,461 $229,000
Q4 2018

Feb 14, 2019

SELL
$3.6 - $8.42 $7,718 - $18,052
-2,144 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$6.33 - $8.08 $13,571 - $17,323
2,144 New
2,144 $17,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $776M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.